---
title: 'Senior Clinical Trial Associate at Dyne Therapeutics'
canonical: 'https://feeny.ai/job/senior-clinical-trial-associate-dyne-therapeutics-waltham-gpmpcd83r8b3'
type: 'job'
last_seen: '2026-09-07'
---

# Senior Clinical Trial Associate at Dyne Therapeutics

- **Company:** Dyne Therapeutics
- **Location:** Waltham, MA
- **Compensation:** $86k–$105k
- **Posted:** 2026-07-15
- **Last confirmed live:** 2026-09-07
- **Apply:** https://job-boards.greenhouse.io/dynetherapeutics/jobs/6115310004

## Job description

Company Overview:

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at [https://www.dyne-tx.com/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaBhdU0rLyxqDF5MLc_hIfw7usSG4P5AlGZUt689alyH6v7mzOmFdpd9s5X8DlnvZSiEkR5UEisX91xRDuQTa2VgG02ByJmFzR8fXOPz8Zi8%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825271389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=J6tnBKJnocuFhoQSNnLD03mlmX8CCP4Ufz89Tz2BRqY%3D&reserved=0), and follow us on [X](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DLBKooGRVe4UrE2Sa6ReueOswzx2nXn5X8MuiTcNNQ_6lX0cFP8Xf24jpFASx3QmF9Qt-1g3RGsigqX34LIiwMg%3D%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825316922%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=1SaJTlzgJLAz3INco8zVJpHByglVu9H3uR4eaUUwqbY%3D&reserved=0), [LinkedIn](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DV9e03kLdDWSbh0_VwnuvS9iTb21RRXsSKiAaMEbducMXKsrR2S-Gw7FLuap5gHCzvcaUIvGPyAeg1wRzFGrqW9J_Z6Ha8bGtJaWV9voKp-c%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825339609%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bDmOn9uD5vB9%2F2LttEyLg%2BANoH6v3vDFv7SAwVdi%2BoI%3D&reserved=0) and [Facebook](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DCMyzCcuOkxGNqTNEki-upZwJJPBCJLp0a-MvjKwwfPo1XQp8XutL02Vy2Vg3ZmpnCYnPLhHxcgEzFeh-07gg_rWzXbiw64-AClVkXbKyKQs%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825359448%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=exQuTFG7FGBX1V0XPy4zSebLvhQUDksB19Nej8Eg3DQ%3D&reserved=0).

Role Summary:

The Senior Clinical Trial Associate (CTA) is a key member of the Clinical Operations team responsible for supporting the successful planning, execution, oversight, and closeout of Dyne’s global clinical trials. This role partners closely with Clinical Study Leads, cross-functional study team members, CROs, vendors, and investigative sites to help ensure trials are delivered with quality, efficiency, compliance, and a strong focus on patients. The Senior CTA contributes to day-to-day study operations, maintains critical study documentation and tracking tools, supports inspection readiness, and helps establish scalable processes and best practices as Dyne continues to advance its clinical development portfolio. Success in this role requires strong organization, attention to detail, proactive communication, sound judgment, accountability, and the ability to manage competing priorities in a dynamic clinical development environment.

This role is based in Waltham, MA.

Primary Responsibilities Include:

- Support the Clinical Study Lead and cross-functional study team across all phases of global clinical trial execution, including feasibility, study planning, start-up, enrollment, maintenance, and closeout activities
- Partner with the Clinical Study Lead to facilitate effective communication across internal study teams, CROs, vendors, and other external partners, helping to proactively identify risks, resolve issues, and keep study activities on track
- Track study metrics, operational milestones, site activation progress, enrollment trends, vendor deliverables, and Sponsor oversight activities; work closely with CROs and vendors to ensure tracking tools are accurate, complete, and current
- Support the review, coordination, and quality control of essential study documents, including informed consent forms, site initiation visit materials, essential regulatory documents, study plans, recruitment materials, manuals, trackers, and other trial-related documents to ensure consistency, accuracy, and compliance
- Assist with the development, routing, distribution, and maintenance of Sponsor study documents and operational materials, such as protocols, protocol amendments, administrative letters, pharmacy manuals, study reference materials, and team communications
- Attend internal study team meetings and external CRO/vendor meetings; prepare and maintain agendas, meeting materials, minutes, decision logs, and action item trackers to support accountability and timely follow-through
- Coordinate logistics and materials for investigator meetings, principal investigator calls, site-facing communications, conferences, vendor meetings, and other study-related forums
- Collect, file, reconcile, and track essential documents for the trial master file (TMF); conduct routine TMF reviews, identify gaps, follow up on missing documentation, and support ongoing inspection readiness activities
- Take initiative to improve Clinical Operations processes by identifying opportunities for standardization, efficiency, quality, and continuous improvement within study teams and across the department
- Maintain and update study tracking tools, dashboards, contact lists, document logs, training records, and other operational resources to support transparency and timely decision-making
- Use sound judgment, intellectual curiosity, and a continuous improvement mindset to identify practical solutions, improve ways of working, and support consistent execution across study teams
- Communicate clearly and professionally with internal and external stakeholders, build effective working relationships, escalate issues appropriately, and follow through on commitments with urgency and attention to quality

Education and Skills Requirements:

- Bachelor’s degree in life sciences, healthcare, or a related field preferred; equivalent combination of education and relevant experience may be considered
- 3+ years of relevant hands-on clinical operations or drug development experience, preferably in a Sponsor setting and with exposure to global or multi-site clinical trials
- Working knowledge of clinical trial operations, ICH-GCP guidelines, regulatory requirements, TMF expectations, and inspection readiness principles
- Experience collaborating across multiple functional areas, such as Clinical Operations, Clinical Development, Regulatory Affairs, Quality Assurance, Data Management, Biostatistics, Medical Writing, Clinical Supply, Finance, and external vendors
- Proficiency with clinical trial tracking systems, document management tools, Microsoft Office applications, and other systems used to support clinical trial execution and documentation
- Demonstrated ability to work independently, collaborate effectively within cross-functional teams, manage competing priorities, and deliver accurate, high-quality work with strong follow-through
- High level of professionalism, discretion, integrity, accountability, and alignment with Dyne’s values and commitment to patients
- Willingness to travel for job-related activities, including investigator meetings, site visits, conferences, or vendor meetings, if required (expected travel for this position is ~5%)

#LI-Onsite MA Pay Range $86,000—$105,000 USD

The pay range reflects the base pay range Dyne reasonably expects to pay for this role at the time of posting. Individual compensation depends on factors such as education, experience, job-related knowledge, and demonstrated skills.

The statements contained herein reflect general details as necessary to describe the principles functions for this job, the level of knowledge and skill typically required, and the scope of responsibility, but should not be considered an all-inclusive listing of work requirements.  Individuals may perform other duties as assigned, including work in other functional areas to cover absences or relief, to equalize peak work periods or otherwise balance workload.

Dyne Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.

## About Dyne Therapeutics

## Company Overview
- **One-liner**: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted nucleic acid therapies for genetically driven neuromuscular diseases using its proprietary FORCE™ platform.
- **Entity Type**: Public (NASDAQ: DYN)
- **Headquarters**: Waltham, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Not publicly available (the company was co-founded by a team of scientists and entrepreneurs; individual names not surfaced in search results)

## Core Business
- **Primary industry**: Biotechnology / Biopharmaceuticals – rare neuromuscular disease therapeutics
- **Target customers**: B2B / B2G – regulatory agencies, healthcare providers, payers, and most importantly patients with Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease.
- **Mission / Purpose**: “Delivering functional improvement for people living with neuromuscular diseases.” [dyne-tx.com](https://www.dyne-tx.com/)

## Products & Services
Dyne’s pipeline is built around its FORCE™ platform, which uses an antigen-binding fragment (Fab) conjugated to transferrin receptor 1 (TfR1) to deliver therapeutic payloads to muscle and the central nervous system.

- **Z‑rostudirsen (DYNE‑251)** – An investigational therapeutic for DMD patients amenable to exon 51 skipping. Consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an anti‑TfR1 Fab. Phase 1/2 DELIVER trial met primary endpoint; BLA submission for U.S. Accelerated Approval planned for Q2 2026 with potential launch in Q1 2027. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Z‑basivarsen (DYNE‑101)** – Investigational therapeutic for DM1, using an antisense oligonucleotide (ASO) conjugated to anti‑TfR1 Fab. Phase 1/2 ACHIEVE trial fully enrolled; Phase 3 HARMONIA trial ongoing. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DYNE‑302** – Preclinical candidate for FSHD, using an siRNA payload to suppress DUX4 expression. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DMD Franchise Expansion** – Four additional development candidates (DYNE‑253, DYNE‑245, DYNE‑244, DYNE‑255) targeting exons 53, 45, 44, and 55 for DMD, entering IND‑enabling studies. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)

## Market Standing
- **Valuation / Market Cap**: Not disclosed in search results (public company; market cap fluctuates with stock price; current figure not provided in the sources).
- **Key Metric**: Cash, cash equivalents and marketable securities of **$1.1 billion** as of December 31, 2025, providing runway into Q1 2028. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Notable Investors / Partners**: Not listed in provided search results (likely institutional investors; prior venture rounds not detailed here).
- **Growth Signals**:
  - Headcount grew **38.2% YoY** to **227 employees** (2025). [linkedin.com](https://www.linkedin.com/company/dynetx)
  - Positive topline results from DELIVER trial for z‑rostudirsen; potential first product launch in Q1 2027 if approved.
  - Advancing five distinct clinical/preclinical programs across multiple neuromuscular indications.

## Competitive Advantages
- **FORCE™ Platform**: Differentiated delivery technology that uses a TfR1‑binding Fab to enable broad and deep tissue penetration in both muscle and CNS – addressing one of the biggest hurdles in neuromuscular drug development.
- **Best‑in‑Class Potential**: Clinical data for z‑rostudirsen showed statistically significant dystrophin expression (5.46% of normal at 6 months, 7‑fold change) and preservation of lung function (FVC%p) compared to placebo, despite a small trial not powered for functional endpoints.
- **Broad Pipeline**: Covering multiple exon‑skipping opportunities in DMD as well as entirely different diseases (DM1, FSHD, Pompe) with the same core platform, reducing risk and enabling rapid expansion.

## Strategic Focus
- **Regulatory Submission**: File a Biologics License Application (BLA) for z‑rostudirsen in Q2 2026 under U.S. Accelerated Approval pathway.
- **Late‑Stage Trials**: Initiate two field‑defining Phase 3 confirmatory trials (FORZETTO for DMD and HARMONIA for DM1) in 2026 following FDA alignment on design.
- **Pipeline Expansion**: Move four additional DMD exon‑skipping candidates into IND‑enabling studies and advance preclinical DYNE‑302 (FSHD) toward the clinic.
- **Commercial Readiness**: Prepare for potential first‑ever company launch in Q1 2027 with a focus on U.S. market, while also pursuing ex‑U.S. approval pathways.

## Why Work Here
- **Mission‑Driven Culture**: The company’s “One Dyne community” ethos emphasizes accountability, transparency, fearlessness, and a relentless drive to deliver functional improvement for patients and families. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Competitive Benefits**: Medical, dental, vision, 401(k), flexible vacation, paid holidays including a year‑end office closure, short‑ & long‑term disability, HSA/FSA accounts. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Work Environment**: Office location in Waltham, MA (Boston area). Remote/hybrid policy not specified in search results; likely on‑site or hybrid for lab‑based roles. Career page lists roles such as Associate Director, Oligonucleotide Development; Scientist, RNA; Director of Training – reflecting a mix of research, clinical, and corporate functions. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/dynetherapeutics)
- **Growth Opportunity**: Joining a late‑stage biotech with a validated platform, strong cash position, and a clear path to commercialization – offering employees exposure to both R&D and upcoming launch activities.
- **Recruitment Scam Warning**: Dyne posts an explicit notice on its careers page that it never requests financial details or payment during hiring; all legitimate emails come from @dyne‑tx.com addresses.

## Sources
1. [dyne-tx.com – Company Overview](https://www.dyne-tx.com/)
2. [dyne-tx.com – Careers & Culture](https://www.dyne-tx.com/careers-culture/)
3. [dyne-tx.com – Pipeline](https://www.dyne-tx.com/pipeline/)
4. [investors.dyne-tx.com – Q4/Full Year 2025 Results](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
5. [linkedin.com – Dyne Therapeutics Company Profile](https://www.linkedin.com/company/dynetx)
6. [job-boards.greenhouse.io – Dyne Careers Page](https://job-boards.greenhouse.io/dynetherapeutics)

## Other roles at Dyne Therapeutics

- [Senior Director, Medical Affairs Learning & Development](https://feeny.ai/job/senior-director-medical-affairs-learning-development-dyne-therapeutics-waltham-mvej99ejr8y0) — Waltham, MA
- [Director, Clinical Scientist](https://feeny.ai/job/director-clinical-scientist-dyne-therapeutics-waltham-jw10cdn5v3ms) — Waltham, MA
- [Scientist, Bioconjugation](https://feeny.ai/job/scientist-bioconjugation-dyne-therapeutics-waltham-jg9q1pw4whag) — Waltham, MA
- [Principal Scientist,  Oligonucleotide (PMO, ASO) Development](https://feeny.ai/job/principal-scientist-oligonucleotide-pmo-aso-development-dyne-therapeutics-2x39whh9swds) — Waltham, MA
- [Director, Drug Safety & Pharmacovigilance Scientist](https://feeny.ai/job/director-drug-safety-pharmacovigilance-scientist-dyne-therapeutics-waltham-6e6cxz3bs5mx) — Waltham, MA
- [Director, People Operations](https://feeny.ai/job/director-people-operations-dyne-therapeutics-waltham-x79gkrh2bafa) — Waltham, MA
- [Associate Director, Talent Acquisition Operations & Programs](https://feeny.ai/job/associate-director-talent-acquisition-operations-programs-dyne-therapeutics-t369xmxga1xg) — Waltham, MA
- [Senior Director, Business Strategy & Operations - Office of the CCO](https://feeny.ai/job/senior-director-business-strategy-operations-office-of-the-cco-dyne-bwjxcnnqeqed) — Waltham, MA
- [Global Medical Director, Medical Affairs](https://feeny.ai/job/global-medical-director-medical-affairs-dyne-therapeutics-waltham-aan9hnpaxh2q) — Waltham, MA
- [Medical Director, Clinical Development](https://feeny.ai/job/medical-director-clinical-development-dyne-therapeutics-waltham-bjcvm54mvn7y) — Waltham, MA